{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:25:29Z","timestamp":1790220329997,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bbmt.2019.02.018","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T19:09:50Z","timestamp":1550862590000},"page":"1271-1280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome"],"prefix":"10.1016","volume":"25","author":[{"given":"Selim","family":"Corbacioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.02.018_bib0001","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0003","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives: a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0005","doi-asserted-by":"crossref","unstructured":"Schechter T, Perez-Albuerne E, Lin TF, et al. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma [e-pub ahead of print]. Bone Marrow Transplant. doi:10.1038\/s41409-018-0298-y. accessed October 4, 2018.","DOI":"10.1038\/s41409-018-0298-y"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0006","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.leukres.2016.03.004","article-title":"Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry","volume":"44","author":"Magwood-Golston","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0008","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0009","doi-asserted-by":"crossref","first-page":"e27269","DOI":"10.1002\/pbc.27269","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinsuoidal obstruction syndrome following nontransplant-associated chemotherapy: final results from a post hoc analysis of data from an expanded-access program","volume":"65","author":"Kernan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0011","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease","volume":"29","author":"DeLeve","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0013","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/imj.13550","article-title":"New insights into sinusoidal obstruction syndrome","volume":"47","author":"Piccin","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0014","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Veno-occlusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0017","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0018","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0019","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0020","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.bbmt.2017.07.021","volume":"23","author":"Bajwa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0021","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2018.07.039","article-title":"Early clinical predictors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after myeloblative stem cell transplantation","volume":"25","author":"Roeker","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0022","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","article-title":"Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant","volume":"24","author":"Strouse","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0023","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0024","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation","volume":"168","author":"Carreras","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0026","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2015.283","article-title":"Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes","volume":"51","author":"Yakushijin","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0027","first-page":"439","article-title":"A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation","volume":"10","author":"Blostein","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0028","doi-asserted-by":"crossref","unstructured":"Kammersgaard MB, Kielsen K, Heilmann C, Ifversen M, M\u00fcller K. Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome [e-pub ahead of print]. Bone Marrow Transplant. doi:10.1038\/s41409-018-0426-8. accessed February 6, 2019.","DOI":"10.1038\/s41409-018-0426-8"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117173","article-title":"Incidence of post-hematopoietic stem cell transplantation (HSCT) veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) without hyperbilirubinemia at diagnosis and efficacy of defibrotide in an expanded-access program [Abstract 2080 ASH 2018]","author":"Corbacioglu","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.bbmt.2019.02.018_bib0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbmt.2018.09.027","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian Hematology-Oncology Association Hematopoietic Stem Cell Transplantation Group","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"Corbacioglu","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0032","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0033","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/17474124.2017.1370372","article-title":"Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation","volume":"11","author":"Corbacioglu","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0034","doi-asserted-by":"crossref","unstructured":"Richardson P, Aggarwal S, Topaglu O, Villa KF, Corbacioglu S. Systematic review of defibrotide studies in the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) [e-pub ahead of print]. Bone Marrow Transplant. doi:10.1038\/s41409-019-0474-8. accessed February 25, 2019.","DOI":"10.1038\/s41409-019-0474-8"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2016.07.011","article-title":"High variability in the reported management of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"22","author":"Skeens","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0036","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/10428194.2015.1041387","article-title":"High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma","volume":"57","author":"Hwang","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0037","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.leukres.2013.06.024","article-title":"Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia","volume":"37","author":"Kim","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0038","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2014.168","article-title":"Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen","volume":"49","author":"Tsirigotis","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0039","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12185-014-1578-y","article-title":"Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant","volume":"99","author":"Maximova","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41409-017-0066-4","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease after high-dose intravenous busulfan\/melphalan conditioning therapy in high-risk Ewing sarcoma","volume":"53","author":"Abate","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0041","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bmt.1701994","article-title":"Late-onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation","volume":"24","author":"Toh","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0042","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.bbmt.2013.09.012","article-title":"Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia","volume":"19","author":"Kato","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0043","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","article-title":"Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients","volume":"13","author":"Carreras","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0044","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3109\/10428194.2012.661052","article-title":"Clinicopathologic features of late-onset veno-occlusive disease\/sinusoidal obstruction syndrome after high-dose intravenous busulfan and hematopoietic cell transplant","volume":"53","author":"Pai","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0045","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood.V99.9.3458","article-title":"HLA-haploidentical blood progenitor cell transplantation in osteopetrosis","volume":"99","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0046","first-page":"1149","article-title":"[Delayed hepatic veno-occlusive disease after haploidentical hematopoietic stem cell transplantation: a report of six cases]","volume":"24","author":"Kang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0047","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0048","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/hpb.12047","article-title":"Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab","volume":"15","author":"Hubert","year":"2013","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0049","first-page":"107","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease complication in lymphoma patients treated with oxaliplatin-based regimen: a case series report","volume":"66","author":"Bernichon","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0051","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0052","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0053","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/bmt.2016.302","article-title":"Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT","volume":"52","author":"Battipaglia","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0054","unstructured":"Wyeth Pharmaceuticals Inc. Mylotarg\u2122 (gemtuzumab ozogamicin) for injection, for intravenous use: full prescribing information."},{"key":"10.1016\/j.bbmt.2019.02.018_bib0055","unstructured":"Wyeth Pharmaceuticals Inc. Besponsa\u2122 (inotuzumab ozogamicin) for injection, for intravenous use: full prescribing information."},{"key":"10.1016\/j.bbmt.2019.02.018_bib0056","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0057","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.12528","article-title":"Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis","volume":"163","author":"Kharfan-Dabaja","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0058","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0059","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0060","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0061","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0062","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S136575","article-title":"Inotuzumab ozogamicin in the treatment of relapsed\/refractory acute B cell lymphoblastic leukemia","volume":"9","author":"Uy","year":"2018","journal-title":"J Blood Med"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0063","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0064","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5045\/br.2015.50.3.123","article-title":"Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation","volume":"50","author":"Lee","year":"2015","journal-title":"Blood Res"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0065","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1046\/j.1365-2141.2002.03748.x","article-title":"Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide","volume":"118","author":"Lee","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0066","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/01.tp.0000183288.67746.44","article-title":"Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients","volume":"80","author":"Pihusch","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0067","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.23213","article-title":"Contribution of fibrinolytic tests to the differential diagnosis of veno-occlusive disease complicating pediatric hematopoietic stem cell transplantation","volume":"58","author":"Sartori","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0068","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.bbmt.2015.07.004","article-title":"Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation","volume":"21","author":"Akil","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0069","doi-asserted-by":"crossref","first-page":"e2454","DOI":"10.1097\/MD.0000000000002454","article-title":"Changes in noninvasive liver fibrosis indices and spleen size during chemotherapy: potential markers for oxaliplatin-induced sinusoidal obstruction syndrome","volume":"95","author":"Park","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0070","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Soubrane","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0071","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejso.2013.12.009","article-title":"Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome","volume":"40","author":"Imai","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0072","doi-asserted-by":"crossref","first-page":"60001","DOI":"10.18632\/oncotarget.18499","article-title":"Evaluation of thromboelastometry parameters as predictive markers for sinusoidal obstruction syndrome in patients undergoing allogeneic stem cell transplantation for acute leukaemia","volume":"8","author":"Rupa-Matysek","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0073","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2017.01.074","article-title":"The role of thromboelastography in pediatric patients with sinusoidal obstructive syndrome receiving defibrotide","volume":"23","author":"Gendreau","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0074","doi-asserted-by":"crossref","unstructured":"Reddivalla N, Robinson AL, Reid KJ, et al. Using liver elastography to diagnose sinusoidal obstruction syndrome in pediatric patients undergoing hematopoetic stem cell transplant [e-pub ahead of print]. Bone Marrow Transplant. doi:10.1038\/s41409-017-0064-6. accessed October 4, 2018.","DOI":"10.1038\/s41409-017-0064-6"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0075","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.7863\/jum.2011.30.11.1593","article-title":"Acoustic radiation force impulse elastography and contrast-enhanced sonography of sinusoidal obstructive syndrome (veno-occlusive disease): preliminary results","volume":"30","author":"Fontanilla","year":"2011","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0076","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/bmt.2016.320","article-title":"Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT","volume":"52","author":"Colecchia","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0077","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejrad.2017.06.025","article-title":"Diagnostic performance of contrast-enhanced CT scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: radio-pathological correlation","volume":"94","author":"Cayet","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0078","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.bbmt.2018.05.025","article-title":"Novel ultrasonographic scoring system of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation","volume":"24","author":"Nishida","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0079","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-016-2998-2","article-title":"Chemotherapy-induced sinusoidal injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis","volume":"17","author":"Stevenson","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0080","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00330-017-5137-9","article-title":"Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation","volume":"28","author":"Park","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0081","doi-asserted-by":"crossref","first-page":"37998","DOI":"10.1038\/srep37998","article-title":"Diagnostic performance of contrast-enhanced CT in pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome","volume":"6","author":"Kan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0082","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.acra.2017.10.012","article-title":"CT features of hepatic veno-occlusive disease: a meta-analysis","volume":"25","author":"Yang","year":"2018","journal-title":"Acad Radiol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0083","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2016-08-735324","article-title":"Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT","volume":"129","author":"Abu Zaid","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0084","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/bmt.2014.16","article-title":"MTHFR C677T\/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome","volume":"49","author":"Efrati","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0085","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00432-014-1857-2","article-title":"Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Seifert","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0086","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood.V81.12.3458.3458","article-title":"Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of veno-occlusive disease of the liver","volume":"81","author":"Faioni","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0087","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bmt.1701445","article-title":"Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study","volume":"22","author":"Lee","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0088","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bmt.1702624","article-title":"Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study","volume":"26","author":"Tanikawa","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0089","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bbmt.2010.02.016","article-title":"Prediction of veno-occlusive disease using biomarkers of endothelial injury","volume":"16","author":"Cutler","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hep.20529","article-title":"Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation","volume":"41","author":"Gooley","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0091","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbmt.2013.11.026","article-title":"Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children","volume":"20","author":"DiCarlo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0092","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.bmt.1703238","article-title":"Organ dysfunction following stem cell transplantation: relationship to plasma cytokine concentrations","volume":"28","author":"McGuire","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0093","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.bbmt.2017.03.021","article-title":"Gastrointestinal toxicity, systemic inflammation, and liver biochemistry in allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Jordan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0094","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/bmt.2017.43","article-title":"Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation","volume":"52","author":"Weischendorff","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.02.018_bib0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/ijh-2017-0015","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome with multiorgan failure","volume":"6","author":"Richardson","year":"2017","journal-title":"Int J Hematol Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119301430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119301430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:07:55Z","timestamp":1761059275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119301430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1083879119301430"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}